Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Cushing Syndrome 5Hypertension 4Diabetes Mellitus, Type 2 4ACTH Syndrome, Ectopic 4Pituitary ACTH Hypersecretion 2Adrenocortical Carcinoma 2Adrenal Cortex Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pathologic Processes 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Hyperglycemia 1Glucose Intolerance 1Fallopian Tube Neoplasms 1Endocrine System Diseases 1Carcinoma, Ovarian Epithelial 1Adrenocortical Hyperfunction 1Adrenal Gland Diseases 1

Interventions

relacorilant 1pembrolizumab 1glutathione pegylated liposomal doxorubicin 1ficlatuzumab 1bosutinib 1Trastuzumab 1Pemetrexed 1Morphine 1Methadone 1MRX-2843 1Imatinib Mesylate 1Cholecalciferol 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pathologic Processes × relacorilant × Clear all
NCT04373265 2024-02-23

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Corcept Therapeutics

Phase 1 Completed
15 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Adrenal Gland Diseases, Adrenocortical Hyperfunction, Cushing Syndrome, Diabetes Mellitus, Type 2, Endocrine System Diseases, Hyperglycemia, Hypertension, Pathologic Processes, Glucose Intolerance, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡